Corient Private Wealth LLC Lowers Holdings in Zimmer Biomet Holdings, Inc. $ZBH

Corient Private Wealth LLC reduced its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 10.6% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 52,546 shares of the medical equipment provider’s stock after selling 6,214 shares during the quarter. Corient Private Wealth LLC’s holdings in Zimmer Biomet were worth $4,793,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of ZBH. Brighton Jones LLC purchased a new stake in Zimmer Biomet during the fourth quarter worth $204,000. Brooklyn Investment Group boosted its stake in shares of Zimmer Biomet by 45.9% during the 1st quarter. Brooklyn Investment Group now owns 461 shares of the medical equipment provider’s stock worth $52,000 after acquiring an additional 145 shares in the last quarter. Wellington Management Group LLP grew its position in shares of Zimmer Biomet by 230.6% during the 1st quarter. Wellington Management Group LLP now owns 36,865 shares of the medical equipment provider’s stock valued at $4,172,000 after acquiring an additional 25,713 shares during the period. Summit Financial LLC increased its stake in shares of Zimmer Biomet by 11.8% in the 1st quarter. Summit Financial LLC now owns 2,151 shares of the medical equipment provider’s stock valued at $244,000 after purchasing an additional 227 shares in the last quarter. Finally, CW Advisors LLC raised its stake in shares of Zimmer Biomet by 8.2% during the 1st quarter. CW Advisors LLC now owns 3,123 shares of the medical equipment provider’s stock worth $353,000 after buying an additional 236 shares during the period. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Stock Down 1.3%

NYSE ZBH opened at $89.25 on Friday. Zimmer Biomet Holdings, Inc. has a 52 week low of $85.33 and a 52 week high of $114.44. The firm has a market cap of $17.69 billion, a PE ratio of 22.09, a P/E/G ratio of 2.34 and a beta of 0.61. The business’s fifty day simple moving average is $94.96 and its 200-day simple moving average is $96.67. The company has a quick ratio of 1.39, a current ratio of 2.43 and a debt-to-equity ratio of 0.59.

Zimmer Biomet (NYSE:ZBH) last posted its earnings results on Wednesday, November 5th. The medical equipment provider reported $1.90 earnings per share for the quarter, beating the consensus estimate of $1.88 by $0.02. Zimmer Biomet had a net margin of 10.05% and a return on equity of 12.85%. The company had revenue of $2 billion for the quarter, compared to analyst estimates of $2.01 billion. During the same period in the previous year, the business posted $1.74 EPS. Zimmer Biomet’s revenue was up 9.6% on a year-over-year basis. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. As a group, equities analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 30th. Investors of record on Tuesday, December 30th will be given a $0.24 dividend. This represents a $0.96 annualized dividend and a yield of 1.1%. The ex-dividend date is Tuesday, December 30th. Zimmer Biomet’s dividend payout ratio is presently 23.76%.

Analyst Upgrades and Downgrades

Several brokerages recently commented on ZBH. Barclays cut their price target on shares of Zimmer Biomet from $112.00 to $105.00 and set an “underweight” rating for the company in a report on Wednesday, November 5th. Johnson Rice set a $112.00 target price on shares of Zimmer Biomet in a research note on Wednesday, November 5th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Zimmer Biomet in a research note on Wednesday, October 8th. Baird R W cut Zimmer Biomet from a “strong-buy” rating to a “hold” rating in a report on Tuesday, December 16th. Finally, Citigroup decreased their price objective on Zimmer Biomet from $98.00 to $94.00 and set a “neutral” rating on the stock in a report on Thursday, December 11th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, twelve have issued a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, Zimmer Biomet has a consensus rating of “Hold” and a consensus price target of $107.50.

Zimmer Biomet Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.